#Milan #Hong Kong #Ascletis #ASC36_35FDC #EASD2026

Introduction

In the ever-evolving landscape of obesity treatment, Ascletis Pharma Inc. has made significant strides with its latest therapeutic candidate, ASC36_35FDC. Recently presented at the 62nd European Association for the Study of Diabetes (EASD) Annual Meeting, held from September 28 to October 2, 2026, in Milan, Italy, this innovative formulation is garnering attention for its promising results in preclinical studies.

What is ASC36_35FDC?

ASC36_35FDC is a unique injectable that combines two key components: ASC36, a peptide amylin receptor agonist, and ASC35, a peptide GLP-1R/GIPR agonist. The drug is designed for flexible dosing schedules, ranging from once a month to once every three months. This flexibility could significantly enhance patient adherence and convenience compared to traditional obesity treatments.

Weight-Loss Efficacy in Preclinical Models

The studies showcased at EASD 2026 involved various preclinical models including diet-induced obesity (DIO) rat models and non-human primates (NHPs). The results indicated a marked reduction in body weight and food intake for the ASC36_35FDC group compared to alternatives like eloralintide/tirzepatide or MET-233i/tirzepatide co-formulations.

During a monitored dosing regimen, data showed that,

• - ASC36_35FDC achieved a 24.8% reduction in body weight by Day 14, significantly outperforming the other formulations (only 12.5% and 16.8% for the other two groups).
• - This correlates with lower food intake, suggesting that the ASC36_35FDC formulation does not just reduce weight but potentially alters appetite control pathways.

Stability and Pharmacokinetics

A crucial aspect of peptide therapies is their formulation stability. ASC36_35FDC has demonstrated excellent chemical and physical stability, with no signs of fibrotic aggregation under various simulated storage conditions. This offers a solid foundation for its development for clinical use.

The pharmacokinetic analysis revealed that ASC36_35FDC has a long half-life, with approximately 33 days for ASC36 and around 30 days for ASC35 in NHPs. This indicates that the drug could successfully leverage a once-monthly or even quarterly dosing schedule in human patients, which may enhance patient compliance and overall treatment experience.

Future Prospects and Conclusion

ASC36_35FDC is a product of Ascletis’ proprietary technologies, including Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD) and Ultra-Long-Acting Platform (ULAP). The ongoing research highlights how combining an amylin receptor agonist with a dual GLP-1R/GIPR agonist can yield substantial improvements in weight management and metabolic health.

As the obesity epidemic continues to rise worldwide, innovative solutions like ASC36_35FDC may provide much-needed breakthroughs in treating this complex condition. The preclinical data support ASC36_35FDC as a promising candidate for future clinical development in combating obesity effectively, making it a significant focus for both researchers and investors alike.
In summary, if clinical trials follow suit and achieve similar encouraging results, ASC36_35FDC could potentially revolutionize the approach to weight management therapies.